Parkinson’s disease (PD) lacks sensitive, objective, and reliable measures for disease progression and response. This presents a challenge for clinical trials given the multifaceted and fluctuating nature of PD symptoms. Innovations in digital health and wearable sensors promise to more precisely measure aspects of patient function and well-being. Beyond research trials, digital biomarkers and clinical outcome assessments may someday support clinician-initiated or closed-loop treatment adjustments. A recent study from Verily Life Sciences presents results for a smartwatch-based motor exam intended to accelerate the development and evaluation of therapies for PD.

帕金森病 (PD) 缺乏对疾病进展和反应的敏感、客观和可靠的措施。鉴于 PD 症状的多面性和波动性，这对临床试验提出了挑战。数字健康和可穿戴传感器的创新有望更精确地测量患者功能和幸福感的各个方面。除了研究试验，数字生物标志物和临床结果评估有朝一日可能会支持临床医生发起或闭环治疗调整。Verily Life Sciences 最近的一项研究展示了基于智能手表的运动检查的结果，旨在加速 PD 疗法的开发和评估。